Our guide on semaglutide burping offers additional management strategies
A 2024 study found that patients taking semaglutide medications were significantly more likely to develop NAION compared to certain other diabetes medications, raising concern about a possible association between GLP-1 drugs and optic nerve injury
Collaboration between primary care providers, endocrinologists, and orthopedic or rheumatology specialists ensures comprehensive care addressing both metabolic health and joint function
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually
Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, et al
1 Pharmacological NMDA receptor antagonism dose-dependently lowers body weight but induces hyperthermia